Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
Novel RNA aptamer designed to inhibit the function of von Willebrand Factor and promote thrombolysis Columbus, Ohio – Sept. 10, 2024 – Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy, today announced that the first patients have been dosed in RAISE, a Phase 2 clinical trial evaluating BB-031 in patients […]
Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke
Financing will fund upcoming Phase 2 trial of BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor (vWF) in development to treat acute ischemic stroke Financing was led by ARCH Venture Partners Columbus, Ohio – Jan. 30, 2024 – Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, […]
Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference
-Phase 2-Ready Drug Candidate Offers Potential to Greatly Broaden the Acute Ischemic Stroke Population Who Can Benefit from Thrombolytic Therapy- Columbus, OH (May 9, 2023): Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus […]
Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023
-BB-031, a potential rapid onset, short-acting and reversible thrombolytic, targets von Willebrand Factor, a key structural component of thrombi and driver of blood clotting- -Company to initiate a Phase 2 clinical proof-of-concept study of BB-031 in patients with acute ischemic stroke- COLUMBUS, OH (February 9, 2023): Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing the […]
Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023
Columbus, OH: January 31, 2023: Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today announced the company will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate at the American Heart Association’s 2023 International Stroke Conference (ISC). The ISC is being held […]
Basking Biosciences, Inc. Completes $5.4M Seed Financing
Funding to support development of the first reversible thrombolytic therapy for acute ischemic stroke Columbus, OH –(BUSINESS WIRE)—Basking Biosciences, Inc. (Basking), a privately-held biopharmaceutical company developing a next generation treatment for acute ischemic stroke (AIS) announced an initial closing of a $5.4M Seed Series financing. The investor syndicate includes Rev1 Ventures, Broadview Ventures and Viva […]
